Navigation Links
BRAF inhibitor shows promising preclinical activity against melanoma
Date:6/15/2010

PHILADELPHIA Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.

The compound also showed partial or complete tumor regression and improved survival in a dose-dependent manner in preclinical efficacy models in rodents, without associated toxicity.

BRAF mutations are found in about 8 percent of all solid tumors but in about 50 percent of melanomas.


"Patients with advanced melanoma currently do not have a lot of options. There are some therapies, but the response rates are very low. Based on this promising preclinical data, we believe this compound merits further study in patients with advanced melanoma," said Dave Heimbrook, Ph.D., global head of discovery oncology at Roche and one of the study authors.

The Cancer Research paper is the first published report of RG7204, which shows tumor regressions in preclinical models. Roche and Plexxikon scientists and their academic collaborators have presented Phase I clinical data at medical meetings.

William Pao, M.D., Ph.D., associate professor of medicine, cancer biology and pathology at Vanderbilt University, said this preclinical research represents a significant step forward in establishing a basis for additional study in melanoma patients.

"This drug will have an impact," said Pao. "The response rates with currently available therapies are only in the 10 percent to 20 percent range, so this represents a large step forward."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert  

Page: 1

Related medicine news :

1. Reportlinker Adds Kinase Inhibitors: Global Markets
2. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
3. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
4. Adoodle Donates NOXO Odor Inhibitor Product to Operation USA to Aid Rescue Workers in Haiti
5. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
6. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. Experimental stem cell treatment arrests acute lung injury in mice, study shows
9. Violence is part of the job say nurses as study shows only 1 in 6 incidents are reported
10. A Study by Celibre Medical Corporation Shows Botox Injections to be the Most Desirable Cosmetic Procedure in Southern California
11. Diabetes patients rank health concerns differently than their doctors, U-M survey shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BRAF inhibitor shows promising preclinical activity against melanoma
(Date:2/5/2016)... ... , ... The American public tends to feel uncomfortable about drinking recycled waste ... or well water. The recent experience with lead contaminated water in Flint, Michigan, according ... toward increasing public acceptance of recycled waste water as drinking water. , The ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and ... 2nd Annual No Cost Dental Day to individuals in need. The event is scheduled ... this No Cost Dental Day is to provide dental care to community members in ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a web ... zone to the next using Colorize's dynamic moving camera. Colorize is perfect for personal ... a 3D slideshow environment with 1 to 5 focus points per scene, stage floor ...
(Date:2/5/2016)... ... , ... California Mobile Kitchens , a company that ... mobile kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. ... anywhere in the U.S. Many of their units can be seen at sporting ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: